---
document_datetime: 2025-12-02 05:03:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vepacel.html
document_name: vepacel.html
version: success
processing_time: 0.1119668
conversion_datetime: 2025-12-26 11:17:20.440858
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vepacel

[RSS](/en/individual-human-medicine.xml/66433)

##### Withdrawn

This medicine's authorisation has been withdrawn

prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vepacel](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 24th September 2020, the European Commission withdrew the marketing authorisation for Vepacel (prepandemic influenza vaccine H5N1 (whole virion, vero cell derived, inactivated)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Ology Bioservices Ireland Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Vepacel was granted marketing authorisation in the EU on 17 February 2012 for prophylaxis of H5N1 subtype of influenza A. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2017. The product had not been marketed in the EU.

The European Public Assessment Report (EPAR) for Vepacel is updated to indicate that the marketing authorisation is no longer valid.

Vepacel : EPAR - Summary for the public

Reference Number: EMA/991112/2011

English (EN) (663.59 KB - PDF)

**First published:** 16/03/2012

**Last updated:** 12/02/2014

[View](/en/documents/overview/vepacel-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-240)

български (BG) (761.01 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/bg/documents/overview/vepacel-epar-summary-public_bg.pdf)

español (ES) (683.55 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/es/documents/overview/vepacel-epar-summary-public_es.pdf)

čeština (CS) (764.39 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/cs/documents/overview/vepacel-epar-summary-public_cs.pdf)

dansk (DA) (658.82 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/da/documents/overview/vepacel-epar-summary-public_da.pdf)

Deutsch (DE) (668.31 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/de/documents/overview/vepacel-epar-summary-public_de.pdf)

eesti keel (ET) (684.17 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/et/documents/overview/vepacel-epar-summary-public_et.pdf)

ελληνικά (EL) (817.51 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/el/documents/overview/vepacel-epar-summary-public_el.pdf)

français (FR) (689.66 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/fr/documents/overview/vepacel-epar-summary-public_fr.pdf)

hrvatski (HR) (683.49 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/hr/documents/overview/vepacel-epar-summary-public_hr.pdf)

italiano (IT) (684.17 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/it/documents/overview/vepacel-epar-summary-public_it.pdf)

latviešu valoda (LV) (763.03 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/lv/documents/overview/vepacel-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (716.26 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/lt/documents/overview/vepacel-epar-summary-public_lt.pdf)

magyar (HU) (713.84 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/hu/documents/overview/vepacel-epar-summary-public_hu.pdf)

Malti (MT) (768.67 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/mt/documents/overview/vepacel-epar-summary-public_mt.pdf)

Nederlands (NL) (663.02 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/nl/documents/overview/vepacel-epar-summary-public_nl.pdf)

polski (PL) (757.53 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/pl/documents/overview/vepacel-epar-summary-public_pl.pdf)

português (PT) (690.28 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/pt/documents/overview/vepacel-epar-summary-public_pt.pdf)

română (RO) (713.68 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/ro/documents/overview/vepacel-epar-summary-public_ro.pdf)

slovenčina (SK) (779.08 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/sk/documents/overview/vepacel-epar-summary-public_sk.pdf)

slovenščina (SL) (756.82 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/sl/documents/overview/vepacel-epar-summary-public_sl.pdf)

Suomi (FI) (693.94 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/fi/documents/overview/vepacel-epar-summary-public_fi.pdf)

svenska (SV) (683.28 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

12/02/2014

[View](/sv/documents/overview/vepacel-epar-summary-public_sv.pdf)

## Product information

Vepacel : EPAR - Product Information

English (EN) (1.22 MB - PDF)

**First published:** 16/03/2012

**Last updated:** 22/01/2019

[View](/en/documents/product-information/vepacel-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-848)

български (BG) (2.52 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/bg/documents/product-information/vepacel-epar-product-information_bg.pdf)

español (ES) (1.24 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/es/documents/product-information/vepacel-epar-product-information_es.pdf)

čeština (CS) (2.07 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/cs/documents/product-information/vepacel-epar-product-information_cs.pdf)

dansk (DA) (1.23 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/da/documents/product-information/vepacel-epar-product-information_da.pdf)

Deutsch (DE) (1.27 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/de/documents/product-information/vepacel-epar-product-information_de.pdf)

eesti keel (ET) (1.22 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/et/documents/product-information/vepacel-epar-product-information_et.pdf)

ελληνικά (EL) (2.54 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/el/documents/product-information/vepacel-epar-product-information_el.pdf)

français (FR) (1.25 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/fr/documents/product-information/vepacel-epar-product-information_fr.pdf)

hrvatski (HR) (1.34 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/hr/documents/product-information/vepacel-epar-product-information_hr.pdf)

íslenska (IS) (1.23 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/is/documents/product-information/vepacel-epar-product-information_is.pdf)

italiano (IT) (1.28 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/it/documents/product-information/vepacel-epar-product-information_it.pdf)

latviešu valoda (LV) (2.12 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/lv/documents/product-information/vepacel-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.32 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/lt/documents/product-information/vepacel-epar-product-information_lt.pdf)

magyar (HU) (2.15 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/hu/documents/product-information/vepacel-epar-product-information_hu.pdf)

Malti (MT) (2.17 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/mt/documents/product-information/vepacel-epar-product-information_mt.pdf)

Nederlands (NL) (1.23 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/nl/documents/product-information/vepacel-epar-product-information_nl.pdf)

norsk (NO) (1.21 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/no/documents/product-information/vepacel-epar-product-information_no.pdf)

polski (PL) (2.17 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/pl/documents/product-information/vepacel-epar-product-information_pl.pdf)

português (PT) (1.24 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/pt/documents/product-information/vepacel-epar-product-information_pt.pdf)

română (RO) (1.35 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/ro/documents/product-information/vepacel-epar-product-information_ro.pdf)

slovenčina (SK) (2.12 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/sk/documents/product-information/vepacel-epar-product-information_sk.pdf)

slovenščina (SL) (2.07 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/sl/documents/product-information/vepacel-epar-product-information_sl.pdf)

Suomi (FI) (1.22 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/fi/documents/product-information/vepacel-epar-product-information_fi.pdf)

svenska (SV) (1.21 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

22/01/2019

[View](/sv/documents/product-information/vepacel-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0019 11/01/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vepacel : EPAR - All Authorised presentations

English (EN) (593.83 KB - PDF)

**First published:** 16/03/2012

**Last updated:** 02/04/2013

[View](/en/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-463)

български (BG) (651.38 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/bg/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_bg.pdf)

español (ES) (594.05 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/es/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_es.pdf)

čeština (CS) (640.27 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/cs/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (593.74 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/da/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (593.84 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/de/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (593.78 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/et/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (651.01 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/el/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_el.pdf)

français (FR) (593.86 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/fr/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (593.86 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/is/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_is.pdf)

italiano (IT) (594.01 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/it/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (641.18 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/lv/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (624.61 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/lt/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (1.18 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/hu/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (1.2 MB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/mt/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (593.75 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/nl/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (593.86 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/no/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_no.pdf)

polski (PL) (641.93 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/pl/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_pl.pdf)

português (PT) (594.05 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/pt/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_pt.pdf)

română (RO) (623.54 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/ro/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (639.38 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/sk/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (625.07 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/sl/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (593.61 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/fi/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (593.87 KB - PDF)

**First published:**

16/03/2012

**Last updated:**

02/04/2013

[View](/sv/documents/all-authorised-presentations/vepacel-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vepacel Active substance Influenza virus (whole virion, inactivated), containing antigen of: A/Vietnam/1203/2004 (H5N1) International non-proprietary name (INN) or common name prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture) Therapeutic area (MeSH)

- Influenza, Human
- Immunization
- Disease Outbreaks

Anatomical therapeutic chemical (ATC) code J07BB01

### Pharmacotherapeutic group

Influenza vaccines

### Therapeutic indication

Active immunisation against H5N1 subtype of influenza A virus.

This indication is based on immunogenicity data from subjects from the age of 6 months onwards following administration of two doses of vaccine prepared with H5N1 subtype strains.

Vepacel should be used in accordance with Official guidance.

## Authorisation details

EMA product number EMEA/H/C/002089 Marketing authorisation holder

Ology Bioservices Ireland LTD

2 Shelbourne Buildings

Marketing authorisation issued 17/02/2012 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vepacel : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (698.65 KB - PDF)

**First published:** 02/04/2013

**Last updated:** 22/01/2019

[View](/en/documents/procedural-steps-after/vepacel-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Vepacel-H-C-2089-P46-0008 : EPAR - Assessment Report

Adopted

Reference Number: EMA/645732/2014

English (EN) (825.91 KB - PDF)

**First published:** 17/11/2014

**Last updated:** 17/11/2014

[View](/en/documents/variation-report/vepacel-h-c-2089-p46-0008-epar-assessment-report_en.pdf)

Vepacel : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/59759/2014

English (EN) (642.43 KB - PDF)

**First published:** 12/02/2014

**Last updated:** 12/02/2014

[View](/en/documents/pip-compliance/vepacel-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Vepacel-H-C-2089-II-0007 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/59623/2014

English (EN) (2.11 MB - PDF)

**First published:** 12/02/2014

**Last updated:** 12/02/2014

[View](/en/documents/variation-report/vepacel-h-c-2089-ii-0007-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Vepacel

Adopted

Reference Number: EMA/CHMP/648050/2013

English (EN) (635.88 KB - PDF)

**First published:** 25/10/2013

**Last updated:** 25/10/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vepacel_en.pdf)

## Initial marketing authorisation documents

Vepacel : EPAR - Public assessment report

Adopted

English (EN) (1.74 MB - PDF)

**First published:** 16/03/2012

**Last updated:** 16/03/2012

[View](/en/documents/assessment-report/vepacel-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vepacel

Adopted

Reference Number: EMA/CHMP/932537/2011

English (EN) (674.81 KB - PDF)

**First published:** 16/12/2011

**Last updated:** 16/12/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vepacel_en.pdf)

#### News on Vepacel

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 October 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-october-2013) 25/10/2013

**This page was last updated on** 28/10/2020

## Share this page

[Back to top](#main-content)